Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Camp4 Therapeutics (CAMP) Shares Outstanding (Diluted Average) (2023 - 2026)

Camp4 Therapeutics' Shares Outstanding (Diluted Average) history spans 3 years, with the latest figure at $30.4 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 547.76% to $30.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $30.4 million, a 547.76% increase, with the full-year FY2025 number at $30.4 million, up 547.76% from a year prior.
  • Shares Outstanding (Diluted Average) hit $30.4 million in Q4 2025 for Camp4 Therapeutics, up from $27.3 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for CAMP hit a ceiling of $30.4 million in Q4 2025 and a floor of $383653.0 in Q3 2023.
  • Historically, Shares Outstanding (Diluted Average) has averaged $10.5 million across 3 years, with a median of $2.6 million in 2024.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): skyrocketed 31.23% in 2024 and later surged 5317.51% in 2025.
  • Tracing CAMP's Shares Outstanding (Diluted Average) over 3 years: stood at $394976.0 in 2023, then skyrocketed by 1087.44% to $4.7 million in 2024, then surged by 547.76% to $30.4 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for CAMP at $30.4 million in Q4 2025, $27.3 million in Q3 2025, and $20.2 million in Q2 2025.